Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications

Drugs of Today

Volumn 47, Issue 4, 2011, Pages 277-288

  Murdaca, Giuseppe ^a   Colombo, B M ^a   Puppo, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; ISONIAZID; LAMIVUDINE; METHOTREXATE; PLACEBO; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

COMBINATION CHEMOTHERAPY; CROHN DISEASE; HEPATITIS B; HUMAN; IMMUNOPATHOLOGY; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; PREGNANCY; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY; TUBERCULOSIS; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; FEMALE; HUMANS; IMMUNE SYSTEM DISEASES; INFLAMMATION; PREGNANCY; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80052748895     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.4.1576692     Document Type: Review

References (70)

1. Taylor, P.C. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003, 3(3): 323-8.
2. Chang, J., Girgis, L. Clinical use of anti-TNF-α biological agents - a guide for GPs. Aust Fam Physician 2007, 36(12): 1035-8.
3. Hochberg, M.C., Lebwohl, M.G., Plevy, S.E., Hobbs, K.F., Yocum, D.E. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005, 34(6): 819-36.
4. Boyce, E.G., Halilovic, J., Stan-Ugbene, O. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor. Clin Ther 2010, 32(10): 1681-703.
5. Launois, R., Avouac, B., Berenbaum, F. et al. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment bayesian metaanalysis. J Rheumatol 2011, Advance publication.
6. Vavricka, S.R., Schoepfer, A.M., Bansky, G. for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2010, Advance publication.
7. Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N., Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975, 72: 3666-70.
8. Hehlgans, T., Pfeffer, K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005, 115(1): 1-20.
9. Peschon, J.J., Torrance, D.S., Stocking, K.L. et al. TNF receptor- deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998, 160(2): 943-52.
10. Roach, D.R., Bean, A.G., Demangel, C., France, M.P., Briscoe, H., Britton, W.J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002, 168(9): 4620-7.
11. Bean, A.G., Roach, D.R., Briscoe, H., France, M.P., Korner, H., Sedgwick, J.D., Britton, W.J. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999, 162(6): 3504-11.
12. Everest, P., Roberts, M., Dougan, G. Susceptibility to Salmonella typhimurium infection and effectiveness of vaccination in mice deficient in the tumor necrosis factor alpha p55 receptor. Infect Immun 1998, 66: 3355-64.
13. Rothe, J., Lesslauer, W., Lotscher, H. et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364: 798-802.
14. Saunders, B.M., Tran, S., Ruuls, S., Sedgwick, J.D., Briscoe, H., Britton, W.J. Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. J Immunol 2005, 174: 4852-9.
15. Bertolini, D.R., Nedwin, G.E., Bringman, T.S., Smith, D.D., Mundy, G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986, 319(6053): 516-8.
16. Lobo, E.D., Hansen, R.J., Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004, 93(11): 2645-68.
17. Emery, P. Role of adalimumab, a novel TNF antagonist in advancing rheumatoid arthritis control. Drugs Today (Barc) 2003, 39 (Suppl. B): 17-23.
18. van der Heijde, D., Breedveld, F.C., Kavanaugh, A., Keystone, E.C., Landewé, R., Patra, K., Pangan, A.L. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5- year results of PREMIER. J Rheumatol 2010, 37(11): 2237-46.
19. Smolen, J.S. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002, 61(4): 290-7.
20. Jamal, S., Patra, K., Keystone, E.C. Response to adalimumab in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. Clin Rheumatol 2009, 28(4): 413-9.
21. Keystone, E.C., Kavanaugh, A.F., Sharp, J.T. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 2004, 50(5): 1400-11.
22. Klareskog, L., van der Heijde, D., de Jager, J.P. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004, 363(9410): 675-81.
23. Lipsky, P.E., van der Heijde, D.M.F.M., St. Clair, E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343(22): 1594-602.
24. Breedveld, F.C., Weisman, M.H., Kavanaugh, A.F. et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54(1): 26-37.
25. Bender, N.K., Heilig, C.E., Dröll, B., Wohlgemuth, J., Armbruster, F.P., Heilig, B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int 2007, 27(3): 269-74.
26. van de Putte, L.B., Atkins, C., Malaise, M. et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63(5): 508-16.
27. Weinblatt, M.E., Keystone, E.C., Furst, D.E. et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48(1): 35-45.
28. Food and Drug Administration. Adalimumab-for use in the treatment of rheumatoid arthritis. Abbott Biologic Licensing Application. http://www.fda.gov/ohrms/dockets/ac/03/ briefing/3930B1-01-C--HUMIRA.Med.Review. pdf. Accessed April 21, 2011.
29. Lovell, D.J., Ruperto, N., Goodman, S. et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008, 359(8): 810-20.
30. Saurat, J.H., Stingl, G., Dubertret, L. et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs.methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008, 158(1): 558-66.
31. Menter, A., Tyring, S.K., Gordon, K. et al. Adalimumab for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008, 58(1): 106-15.
32. Simpson, D., Scott, L.J. Adalimumab in psoriatic arthritis. Drugs 2006, 66(11): 1487-98.
33. Mease, P., Gladman, D.D., Ritchlin, C.T. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52(10): 3279-89.
34. Saougou, I., Markatseli, T.E., Papagoras, C., Voulgari, P.V., Alamanos, Y., Drosos, A.A. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5- year open-label observational cohort study. Semin Arthritis Rheum 2011, 40(5): 398-406.
35. Haibel, H., Rudwaleit, M., Brandt, H.C. et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two week openlabel trial. Arthritis Rheum 2006, 54(2): 678-81.
36. van der Heijde, D., Kivitz, A., Schiff, M.H. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2006, 54(7): 2136-46.
37. Cassinotti, A., Ardizzone, S., Porro, G.B. Adalimumab for the treatment of Crohn's disease. Biologics 2008, 2(4): 763-77.
38. Hanauer, S.B., Sandborn, W.J., Rutgeerts, P. et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130(2): 323-33.
39. Sandborn, W.J., Rutgeerts, P., Enns, R. et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146(12): 829-38.
40. Sandborn, W.J., Hanauer, S.B., Rutgeerts, P. et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56(9): 1232-9.
41. Colombel, J.F., Sandborn, W.J., Rutgeerts, P. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132(1): 52-65.
42. Rudwaleit, M., Rødevand, E., Holck, P., Vanhoof, J., Kron, M., Kary, S., Kupper, H. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009, 68(5): 696-701.
43. Braun, J., Baraliakos, X., Listing, J., Sieper, J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52(8): 2447-51.
44. Guignard, S., Gossec, L., Salliot, C., Ruyssen-Witrand, A., Luc, M., Duclos, M., Dougados, M. Efficacy of tumour necrosis factors blockers in reducing uveitis flares in spondyloarthropathy: a retrospective study. Ann Rheum Dis 2006, 65(12): 1631-4.
45. Peyrin-Biroulet, L., Laclotte, C., Roblin, X., Bigard, M.A. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007, 13(16): 2328-32.
46. Oussalah, A., Laclotte, C., Chevaux, J.B. et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: A single-centre experience. Aliment Pharmacol Ther 2008, 28(8): 966-72.
47. Afif, W., Leighton, J.A., Hanauer, S.B. et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009, 15(9): 1302-7.
48. Taxonera, C., Estellés, J., Fernández-Blanco, I. et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011, 33(3): 340-8.
49. Gies, N., Kroeker, K.I., Wong, K., Fedorak, R.N. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010, 32(4): 522-8.
50. Reinisch, W., Sandborn, W.J., Hommes, D.W. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis. Gastroenterology 2010, 138(Suppl. 1): S114-5.
51. Winthrop, K.L. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006, 2(11): 602-10.
52. Tsiodras, S., Samonis, G., Boumpas, D.T., Kontoyiannis, D.P. Fungal infections complicating tumor necrosis factor α blockade therapy. Mayo Clin Proc 2008, 83(2): 181-94. (Pubitemid 351303102)
53. De Keyser, F., Van den Bosch, F., Mielants, H. Anti-TNF-α therapy in ankylosing spondylitis. Cytokine 2006, 33(5): 294-8.
54. Tektonidou, M.G., Skopouli, F.N. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol 2008, 27(4): 541-2.
55. Kim, Y.J., Bae, S.C., Sung, Y.K. et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-α blocker in the treatment of rheumatic diseases. J Rheumatol 2010, 37(2): 346-50.
56. Loras, C., Gisbert, J.P., Mínguez, M. et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010, 59(10): 1340-6.
57. Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L., Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295(19): 2275-85.
58. Galloway, J.B., Hyrich, K.L., Mercer, L.K. et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011, 50(1): 124-31.
59. Genovese, M.C., Bathon, J.M., Martin, R.W. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46: 1443-50.
60. Gonnet-Gracia, C., Barnetche, T., Richez, C., Blanco, P., Dehais, J., Schaeverbeke, T. Anti-nuclear antibodies, anti- DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-α blockers. Clin Exp Rheumatol 2008, 26(3): 401-7. (Pubitemid 352003207)
61. Mohan, N., Edwards, E.T., Cupps, T.R. et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritis. Arthritis Rheum 2001, 44(12): 2862-9.
62. Berthelot, C.N., Gorge, S.J., Hsu, S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol 2005, 53(5 Suppl. 1): S260-2.
63. Stallmach, A., Hagel, S., Bruns, T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 2010, 24(2): 167-82.
64. Khanna, D., McMahon, M., Furst, D.E. Anti-tumor necrosis factor α therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 2004, 50(4): 1040-50.
65. Cuchacovich, R., Espinoza, C.G., Virk, Z., Espinoza, L.R. Biologic therapy (TNF-α antagonists)-induced psoriasis: a cytokine imbalance between TNF-α and IFN-α? J Clin Rheumatol 2008, 14(6): 353-6.
66. Roux, C.H., Brocq, O., Breuil, V., Albert, C., Euller-Ziegler, L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology 2007, 46(4): 695-8. (Pubitemid 46523319)
67. Dessinioti, C., Stefanaki, I., Stratigos, A., Kostaki, M., Katsambas, A., Antoniou, C. Pregnancy during adalimumab use for psoriasis. J Eur Acad Dermatol Venereol 2010, Advance publication.
68. Jürgens, M., Brand, S., Filik, L. et al. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis 2010, 16(10): 1634-6.
69. El Mourabet, M., El-Hachem, S., Harrison, J.R., Binion, D.G. Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. Curr Drug Targets 2010, 11(2): 234-41.
70. Gisbert, J.P. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm Bowel Dis 2010, 16(5): 881-95.